Scarica l'app Stockscreener
29.07
3.05%
0.86
Precedente Chiudi:
$28.21
Aprire:
$28.83
Volume 24 ore:
744.00K
Relative Volume:
0.77
Capitalizzazione di mercato:
$1.73B
Reddito:
-
Utile/perdita netta:
$-131.11M
Rapporto P/E:
-13.37
EPS:
-2.1745
Flusso di cassa netto:
$-102.47M
1 W Prestazione:
+14.36%
1M Prestazione:
-21.52%
6M Prestazione:
+28.63%
1 anno Prestazione:
+203.13%
Intervallo 1D:
$28.48
$29.59
Intervallo di 1 settimana:
$24.66
$29.59
Portata 52W:
$8.98
$40.65
Tyra Biosciences Inc Stock (TYRA) Company Profile
Nome
Tyra Biosciences Inc
Settore
Industria
Telefono
(619) 728-4760
Indirizzo
2656 STATE STREET, CARLSBAD
Compare TYRA vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
TYRA
Tyra Biosciences Inc
|
29.07 | 1.70B | 0 | -131.11M | -102.47M | -2.1745 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Tyra Biosciences Inc Stock (TYRA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-15 | Iniziato | Guggenheim | Buy |
| 2026-04-06 | Iniziato | Canaccord Genuity | Buy |
| 2026-02-24 | Iniziato | Cantor Fitzgerald | Overweight |
| 2026-02-10 | Iniziato | William Blair | Outperform |
| 2026-01-28 | Iniziato | Barclays | Overweight |
| 2025-09-03 | Iniziato | Raymond James | Strong Buy |
| 2025-05-21 | Ripresa | Piper Sandler | Overweight |
| 2025-01-07 | Iniziato | UBS | Buy |
| 2024-10-18 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2024-08-15 | Iniziato | Piper Sandler | Overweight |
| 2023-12-15 | Downgrade | BofA Securities | Buy → Neutral |
| 2023-06-30 | Iniziato | Wedbush | Outperform |
| 2023-02-03 | Iniziato | Oppenheimer | Outperform |
| 2022-06-23 | Iniziato | H.C. Wainwright | Buy |
| 2022-03-08 | Aggiornamento | Jefferies | Hold → Buy |
| 2021-11-08 | Downgrade | Jefferies | Buy → Hold |
| 2021-10-11 | Iniziato | BofA Securities | Buy |
| 2021-10-11 | Iniziato | Cowen | Outperform |
| 2021-10-11 | Iniziato | Jefferies | Buy |
Mostra tutto
Tyra Biosciences Inc Borsa (TYRA) Ultime notizie
TYRA Q1 2026 Earnings: EPS Miss Amid Pre-Revenue Stage, Stock Gains 5.55%Earnings Seasonality - newsline.com
Tyra Biosciences (TYRA) Surges 5.55% on Strong Volume, Testing Key Resistance LevelsCash Flow Strong Stocks - newsline.com
Is Tyra Biosciences (TYRA) Too Reliant On Dabogratinib Amid Renewed SURF-302 Skepticism? - Yahoo Finance
Urothelial Carcinoma Market on Track for Major Expansion - openPR.com
Urothelial Carcinoma Market on Track for Major Expansion by 2036, According to DelveInsight | Bristol-Myers Squibb, Astellas Pharma, Pfizer, Johnson & Johnson, Pfizer, Tyra Biosciences, Infinity - Barchart.com
BofA Securities Maintains TYRA BIOSCIENCES, INC.(TYRA.US) With Buy Rating, Raises Target Price to $42 - Moomoo
Tyra Biosciences' Weak Investor Sentiment Reflects Macro Pressures, Renewed SURF-302 Concerns, BofA Says - Moomoo
TYRA Maintains Rating by B of A Securities -- Price Target Raised to $42 - GuruFocus
Tyra Biosciences, Inc. Stock 12‑Month Price Target Cut to $50.8, Implies 96% Upside - TradingView
BofA Securities Raises Price Target on Devon Energy to $42 From $37, Buy Rating Kept - marketscreener.com
BofA raises Tyra Biosciences stock price target on safety outlook By Investing.com - Investing.com Nigeria
Analyst Initiates Buy on Tyra Biosciences, Citing De-Risked Dabogratinib Program and Attractive Entry Ahead of Key Bladder Cancer Data - TipRanks
BofA raises Tyra Biosciences stock price target on safety outlook - Investing.com
TYRA Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Tyra Biosciences (TYRA) Declines 1.67% as Stock Tests Key Support LevelsCovered Call Trade - newsline.com
Raymond James reiterates Strong Buy on Tyra Biosciences stock amid recent weakness - Investing.com Canada
TYRA: Dabogratinib advances in three FGFR3-driven indications, with pivotal data readouts ahead - TradingView
Tyra Biosciences Shareholders Reelect Directors and Ratify Auditor - TipRanks
Tyra Biosciences (NASDAQ: TYRA) details 2026 shareholder meeting voting outcomes - Stock Titan
Tyra Biosciences (TYRA) director option grant tied to RA Capital funds - Stock Titan
Tyra Biosciences (TYRA) director awarded 13,160 stock options at $32.68 strike - Stock Titan
Tyra Biosciences (TYRA) director granted 13,160 stock options at $32.68 - Stock Titan
Tyra Biosciences (TYRA) director option grant held for RA Capital funds - Stock Titan
Tyra Biosciences (NASDAQ: TYRA) grants 13,160 stock options to director Adele Gulfo - Stock Titan
Director at Tyra Biosciences (NASDAQ: TYRA) awarded stock options - Stock Titan
Tyra Biosciences (TYRA) director granted 13,160 stock options - Stock Titan
[144] Tyra Biosciences, Inc. SEC Filing - Stock Titan
Tyra Biosciences Expands Precision Oncology Clinical Pipeline - asatunews.co.id
Tyra Biosciences Reports Net Loss and Advances Cancer Drug Strategy - HarianBasis.co
Wolfe Research Initiates Peer Perform rating on Tyra Biosciences, Inc. (TYRA) - Yahoo Finance
TYRA Q1 2026 Earnings: Wider-than-Expected Loss as Pre-Revenue Biotech Advances Pipeline - newsline.com
Tyra Biosciences (TYRA) Gains 2.23% as Speculative Interest Returns to BiotechKAMA Signal - The Legal Advocate
What's Driving Tyra Biosciences' Recent Surge - Kavout
Tyra Biosciences (TYRA) Advances 2.23% as Stock Closes Near Resistance at $35.08Up Down Ratio - newsline.com
Tyra Biosciences Inc. (TYRA) Faces Modest Decline as Shares Test Key Support ZoneVolume Profile - The Legal Advocate
Tyra Biosciences Inc. (TYRA) Q1 2026 Earnings: Wider-Than-Expected Loss as Clinical Pipeline Progress ContinuesEarnings Quality Analysis - newsline.com
CCORF Maintains TYRA BIOSCIENCES, INC.(TYRA.US) With Buy Rating, Maintains Target Price $50 - Moomoo
How Tyra Biosciences Inc. (TYRA) Affects Rotational Strategy Timing - Stock Traders Daily
This Tyra Biosciences Insider Reduced Their Stake By 58% - Moomoo
Tyra Biosciences (TYRA) Surges 3.45% as Biotech Momentum BuildsNHNL Ratio - newsline.com
TYRA Pulls Back: Market Rotation Hits Communication - Newser
Tyra Biosciences, Inc. Stock 12‑Month Price Target Raised to $51.78, Implies 59% Upside - TradingView
William Blair Maintains TYRA BIOSCIENCES, INC.(TYRA.US) With Buy Rating - Moomoo
Tyra Biosciences Stock Has a Data Question Investors Can’t Ignore - Bez Kabli
Tyra Biosciences (TYRA) Slips Slightly as Stock Holds Between Key Support and Resistance LevelsBuffered ETF - The Legal Advocate
TYRA BIOSCIENCES AND BCAN ESTABLISH MAY 21 AS UPPER TRACT UROTHELIAL CANCER (UTUC) AWARENESS DAY - PR Newswire
Tyra Biosciences (TYRA) Q1 2026 Miss: What Went WrongCommunity Buy Signals - Newser
Wolfe Research initiates coverage of Tyra Biosciences (TYRA) with peer perform recommendation - MSN
Tyra Biosciences (TYRA) Q1 2026 Disappoints — EPS $-0.64 Below $-0.60 ViewsAnalyst Consensus Shift - Newser
TYRA Initiates Coverage On Wolfe Research -- Rating Set to Peer Perform - GuruFocus
Wolfe Research initiates Tyra Biosciences stock at Peerperform By Investing.com - Investing.com Canada
Tyra Biosciences Inc Azioni (TYRA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.60%
0.94%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):